Oct 07, 2013|3 min readBy Amy SwindermanAmgen’s big bang theorySeeking to stave off generic competition, Amgen spends $10.4 billion to acquire Onyx and its FDA-approved cancer drug, Kyprolis
May 05, 2011|3 min readAmgen expands footprintCompany acquires Bergamo, agrees to reacquire rights to products from Hypermarcas
Jun 07, 2007|1 min readBy Randall C WillisAmgen goes shoppingExpanding its drug pipeline externally, Amgen acquires Ilypsa and Alantos Pharmaceuticals for $420 million and $300 million, respectively.
Jun 22, 2015|3 min readBy Jeffrey BouleyPhase 3 results encouraging for Amgen’s panitumumab drug for colorectal cancerTrial for Vectibix indicates improved overall survival in chemorefractory wild-type KRAS metastatic colorectal cancer vs. best supportive care
Mar 06, 2014|3 min readBy Lloyd DunlapDako and Amgen expand collaborationThe partners plan to develop a molecular diagnostic test using Dako’s IQFISH buffer
Jul 24, 2007|3 min readBy Chris AndersonAmgen goes on buying bingeBiotech leader Amgen to acquire Ilypsa and Alantos for combined $720 million
Aug 28, 2014|3 min readBy Kelsey KaustinenAmgen submits BLA for cholesterol drugIn Phase 3 trial, evolocumab successfully reduced LDL cholesterol, showed good safety results and limited adverse effects
May 28, 2013|2 min readBy Kelsey KaustinenAmgen, Astellas unite in strategic allianceAgreement includes a long-term co-development and co- commercialization collaboration and the establishment of a joint venture in Japan